Novo Nordisk has received approval from the US Food and Drug Administration (FDA) for basal insulin Awiqli. Awiqli is a solution for injection with a concentration of 700 units/ml. It is intended for adult patients with type 2 diabetes. This is basal insulin, which is used to keep blood sugar levels stable between meals and during sleep. FDA approval allows Novo Nordisk to bring Awiqli to the US market.